Celsius vs. Dutch Bros: Which Growth Stock Wins in This Market?

Celsius is benefiting from the 2025 acquisition of Alani Nu, with consensus calling for revenue growth of 20% from 2026 to 2028 and diluted EPS growth of 55%. Dutch Bros reported 1,136 stores at the end of 2025 and is targeting 2,029 locations by 2029, while same-store sales have risen for 11 straight quarters and net income jumped 76.4% in 2025. The article is comparative and valuation-focused, noting Dutch Bros trades at a richer 2028 EPS multiple but may have a lower-risk growth path than Celsius.

Analysis

The key second-order issue is that both names are really arguing for scarce shelf-space and habit formation, not just unit growth. CELH’s acquisition-driven portfolio build can broaden occasions and defend velocity, but it also raises execution risk: integration, channel conflict, and margin mix could matter more than top-line print quality over the next 2-4 quarters. BROS, by contrast, is turning store-count growth into a compounding local-network effect; the real valuation debate is whether that network starts lowering customer acquisition cost and labor waste enough to justify the premium multiple.

The market may be underpricing how quickly operating leverage can re-rate BROS if same-store sales stay positive while new units mature. A 1-2 point margin inflection in a chain at this stage can matter more than headline revenue growth, because small changes in store-level economics cascade into long-duration EPS revisions. The flip side is that CELH’s faster consensus EPS growth can be a trap if competitive intensity forces promotional spend or slotting concessions; that risk is often hidden until growth slows for a quarter or two.

Contrarianly, the cleaner trade may be to own the business with the more visible unit economics and short the one with the more fragile brand architecture. If consumer spending softens, premium beverage innovation is easier to defer than a daily coffee habit, but BROS is also more exposed to discretionary traffic and wage inflation, so it is the better long-term compounder but not the lower-volatility trade. The next 6-12 months likely hinge on whether CELH can prove post-acquisition synergies without sacrificing velocity, while BROS needs continued positive comps to keep its valuation from compressing despite growth.

Key Decisions for Investors

• Long BROS / short CELH as a 6-12 month relative-value pair: thesis is that BROS' store-level compounding and operating leverage are more durable, while CELH's post-M&A integration and competitive spending create a higher probability of estimate resets.
• If initiating CELH long exposure, use a staged entry over the next 1-2 earnings cycles rather than chasing momentum; the risk/reward is better after any digestion period or on evidence that Alani Nu is accretive without margin dilution.
• For BROS, prefer call spreads or a smaller outright long rather than full-size equity: upside remains tied to unit expansion and comp leverage, but valuation leaves less room for a clean multiple expansion from here.
• Watch for any 1Q/2Q guide language around promotional intensity, gross margin, or store-level labor; a negative inflection there would likely hit CELH first and could trigger a 10-15% multiple de-rating quickly.
• If consumer discretionary data weakens, rotate from CELH/BROS beta into a pair hedge with a defensive consumer name; BROS should hold comp better, but both are vulnerable if traffic slows and wage inflation re-accelerates.